Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis.
Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories of Dr. Alan Kozikowski at the University of Illinois-Chicago and the Center for Developmental Therapeutics at Northwestern University.
The company is led by a senior management and scientific team with decades of pharmaceutical industry experience leading successful discovery, development, and commercialization of new therapeutic agents and health related technologies.
The initial clinical study with our lead molecule, 9-ING-41, Clinical Study 1801 (Clinicaltrials.gov), is actively enrolling patients. This Phase 1/2 protocol is designed to move safely, seamlessly, and efficiently from patient treatment with single-agent 9-ING-41 to treatment with 9-ING-41 combined with cornerstone cytotoxic agents and then to cancer-specific Phase 2 efficacy studies, the first of which is focused on treating patients with metastatic pancreatic cancer.
Actuate is currently recruiting patients in a Phase 2 study (1901) (Clinicaltrials.gov) focused on the treatment of myelofibrosis which will establish the value of 9-ING-41 as a single agent or in combination with Ruxolitinib in patients with advanced disease.
Our 1902 study (Clinicaltrials.gov), a Phase 1 study of 9-ING-41 as a single agent or in combination with Irinotecan in pediatric patients with refractory cancers, is also underway.
9-ING-41 is a Best-in-Class agent, with ongoing research continuing to show significant anti-tumor activity in multiple models of refractory cancers, including those of the pancreas, brain, lung, breast and the lymphomas. We are unaware of any published research demonstrating the degree of GSK-3 inhibitor-related efficacy in multiple treatment-resistant cancers which has been observed with 9-ING-41. Importantly, in rigorous preclinical and clinical testing, 9-ING-41 demonstrated superior toxicity and pharmacokinetic attributes.